Safety and tolerability of single low-dose primaquine in a low-intensity transmission area in South Africa: an open-label, randomized controlled trial.

Jaishree RamanElizabeth AllenLesley WorkmanAaron MabuzaHendrik SwanepoelGillian MalatjeJohn FreanLubbe WiesnerKaren I Barnes

Published in: Malaria journal (2019)

Safety, tolerability, CYP2D6 and G6PD variant data from this study support the deployment of the WHO-recommended SLD primaquine without G6PD testing to advance malaria elimination in South African districts with low-intensity residual transmission. Trial registration Pan African Clinical Trial Registry, PACTR201611001859416. Registered 11 November 2016, https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=1859.

Keyphrases

clinical trial
open label
study protocol
randomized controlled trial
low dose
south africa
phase ii
phase iii
double blind
placebo controlled
high dose
hiv positive
plasmodium falciparum
data analysis
human immunodeficiency virus